Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting tags : Treatment save search
Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
CLNN S | $0.332 -4.93% -5.18% 550K
|
| Email alert
Add to watchlist
au8 neurology sclerosis treatment for meeting
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
Published: 2024-04-15 (Crawled : 21:00) - globenewswire.com
ZVRA | $4.57 1.11% 1.09% 110K
|
n/a
|
| O: 1.15%
H: 1.03%
C: -1.45%
disease treatment for meeting therapeutics
Soil Treatment Market size is set to grow by USD 16.46 billion from 2023-2027, Need to meet rising demand for crops boost the market, Technavio
Published: 2024-04-10 (Crawled : 13:30) - prnewswire.com
CODYY | $15.06 -0.13% 99K
|
Manufacturing
|
| O: -3.01%
H: 1.44%
C: 0.84%
treatment for set market
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.15 0.94% 0.93% 19K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | News 0 d | $11.96 1.53% 1.51% 190K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Bristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
Published: 2024-03-20 (Crawled : 12:00) - biospace.com/
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: -0.33%
H: 1.02%
C: 0.48%
opdivo treatment trial advanced plus
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
Published: 2024-03-19 (Crawled : 21:00) - globenewswire.com
AEON | $4.72 1.29% -0.85% 72K
|
|
| O: -4.03%
H: 7.45%
C: -8.9%
abp-450 fda update treatment biopharma meeting migraine
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
CANF | $1.91 -3.54% 3.67% 8.7K
|
Health Technology
|
| O: -0.45%
H: 2.27%
C: 2.27%
europe liver conference distribution pancreatic treatment namodenoson
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Published: 2024-03-11 (Crawled : 01:00) - prnewswire.com
SGMT | News | $4.02 0.25% 0.25% 300K
|
Health Technology
|
| O: 1.04%
H: 2.24%
C: -5.68%
asc40 presentation treatment meeting acne results study
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-03-06 (Crawled : 13:30) - prnewswire.com
GNPX | $2.15 0.94% 0.93% 19K
|
Health Technology
|
| O: 24.27%
H: 5.66%
C: -14.45%
reqorsa lung positive treatment system preclinical meeting therapy
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Published: 2024-02-22 (Crawled : 12:00) - globenewswire.com
PHVS | $20.69 7.99% 7.39% 51K
|
|
| O: -0.22%
H: 3.95%
C: 0.11%
deucrictibant positive treatment meeting results study
Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Published: 2024-01-05 (Crawled : 14:30) - biospace.com/
COYA | News | $7.96 -0.5% -0.5% 38K
|
|
| O: 1.94%
H: 2.79%
C: 0.0%
fda sclerosis treatment therapeutics
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
Published: 2024-01-04 (Crawled : 12:30) - globenewswire.com
VRCA | $6.81 -2.44% -2.5% 310K
|
Health Technology
|
| O: -0.44%
H: 2.51%
C: -0.89%
fda treatment pharmaceuticals meeting
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
Published: 2023-12-18 (Crawled : 23:00) - biospace.com/
CYTH | $1.26 8.62% 7.94% 84K
|
Professional, Scientific, and T...
|
| O: 8.03%
H: 0.54%
C: -6.76%
trappsol fda disease positive treatment meeting program therapeutics
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
Published: 2023-11-13 (Crawled : 12:00) - globenewswire.com
AVIR | $3.68 -1.08% -1.09% 350K
|
Health Technology
|
| O: 3.1%
H: 0.0%
C: -3.68%
hepatitis liver bemnifosbuvir treatment pharmaceuticals meeting virus
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
ALGS | $0.805 7.33% 6.83% 470K
|
Health Technology
|
| O: 0.0%
H: 1.3%
C: -9.26%
alg-0001 meeting hepatitis liver alg-000184 positive treatment therapeutics results
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
Published: 2023-11-09 (Crawled : 16:00) - globenewswire.com
PHVS | $20.69 7.99% 7.39% 51K
|
|
| O: -1.16%
H: 0.0%
C: -1.47%
treatment meeting
Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
SCPS | $0.1682
|
| Email alert
Add to watchlist
cancer treatment immunotherapy meeting
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule, and Updates on Several Preclinical Candidates for the Treatment of Chronic Hepatitis B, in Addition to the Recently Announced Late Breaker Poster (#5028-C)
Published: 2023-11-07 (Crawled : 13:00) - globenewswire.com
ALGS | $0.805 7.33% 6.83% 470K
|
Health Technology
|
| O: 5.13%
H: 0.13%
C: -7.88%
alg-0550 meeting hepatitis liver agonist treatment preclinical therapeutics
GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Published: 2023-11-06 (Crawled : 14:30) - globenewswire.com
GTBP | $3.97 7.59% 7.05% 3.5K
|
Manufacturing
|
| O: -3.42%
H: 21.59%
C: 3.54%
gtb-5550 trike positive cancer treatment biopharma preclinical immunotherapy meeting
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.